Allogene Therapeutics (ALLO) Common Equity (2018 - 2026)
Allogene Therapeutics (ALLO) posted Common Equity of $278.9 million for Q1 2026, down 4.67% sequentially from $292.5 million in Q4 2025, and down 27.64% YoY from $385.4 million in Q1 2025.
Allogene Therapeutics (ALLO) Common Equity (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Common Equity for 9 years, with the latest figure at $278.9 million in Q1 2026.
- Quarterly Common Equity fell 27.64% year-over-year to $278.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $278.9 million (down 27.64% YoY) and the FY2025 annual result came in at $292.5 million, down 30.71% from the prior year.
- Common Equity eased to $278.9 million in Q1 2026 per ALLO's latest filing, from $292.5 million in the prior quarter.
- Over five years, Common Equity peaked at $865.3 million in Q1 2022 and troughed at $278.9 million in Q1 2026.
- A 5-year average of $521.6 million and a median of $512.2 million in 2023 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 16.47% in 2025, down 33.1% in 2025.
- Over 5 years, Common Equity stood at $666.9 million in 2022, then slipped by 23.19% to $512.2 million in 2023, then slipped by 17.58% to $422.2 million in 2024, then slumped by 30.71% to $292.5 million in 2025, then retreated by 4.67% to $278.9 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $278.9 million, $292.5 million, and $315.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | 436.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 436.18 Mn |
| Mar 31, 2026 | 278.88 Mn |
| Dec 31, 2025 | 292.54 Mn |
| Sep 30, 2025 | 315.33 Mn |
| Jun 30, 2025 | 344.56 Mn |
| Mar 31, 2025 | 385.39 Mn |
| Dec 31, 2024 | 422.18 Mn |
| Sep 30, 2024 | 463.75 Mn |
| Jun 30, 2024 | 515.04 Mn |
| Mar 31, 2024 | 461.37 Mn |
| Dec 31, 2023 | 512.23 Mn |
| Sep 30, 2023 | 580.64 Mn |
| Jun 30, 2023 | 621.41 Mn |
| Mar 31, 2023 | 592.01 Mn |
| Dec 31, 2022 | 666.88 Mn |
| Sep 30, 2022 | 743.40 Mn |
| Jun 30, 2022 | 806.48 Mn |
| Mar 31, 2022 | 865.27 Mn |
| Dec 31, 2021 | 925.20 Mn |
| Sep 30, 2021 | 969.94 Mn |